KYONGBO PHARMACEUTICAL CO., LTD. Logo

KYONGBO PHARMACEUTICAL CO., LTD.

Manufactures APIs and finished drugs, offering global CDMO services from development to production.

214390 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
충청남도 아산시 실옥로 174, 아산시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kyongbo Pharmaceutical Co., Ltd., established in 1987, is a pharmaceutical company specializing in the research, development, and manufacturing of Active Pharmaceutical Ingredients (APIs) and finished drug products. The company's portfolio includes general APIs, sterile APIs for cephalosporin and carbapenem injectables, and high-potency APIs for anticancer treatments. It also manufactures finished dosage forms, including solid oral drugs and sterile injectables. In addition to its own product lines, Kyongbo operates as a Contract Development and Manufacturing Organization (CDMO), providing integrated services from early-stage development through commercial cGMP production for a global client base. The company leverages its extensive experience and dedicated research facilities to innovate within the pharma-chemical sector.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-09 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 50.4 KB
2025-09-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-09-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 115.4 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1021.1 KB
2025-07-31 00:00
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
Korean 41.0 KB
2025-07-25 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 13.3 KB
2025-07-09 00:00
Legal Proceedings Report
[기재정정]주요사항보고서(영업정지)
Korean 13.0 KB
2025-07-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-07-02 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 34.7 KB
2025-07-02 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 108.5 KB
2025-06-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.6 KB
2025-06-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.6 KB
2025-06-18 00:00
Legal Proceedings Report
[기재정정]주요사항보고서(영업정지)
Korean 13.4 KB
2025-06-17 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-06-17 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 35.5 KB

Automate Your Workflow. Get a real-time feed of all KYONGBO PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for KYONGBO PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.